In reading through both trials from the US and Japan, there is a major difference in the dose of Xeloda given to participants. The US trial (as per the above article) is 1000 mg per day and the Japanese trail (Create-X) is 2500 mg per day. Could this be the reason for the difference in results?
As discussed in the US article shared above, agree that more research is needed to individualize treatment given there are many sub types of TNBC, but don't discount this treatment option if it applies to you until you talk to your oncologist.
Edited by JenAus01 - Dec 12 2018 at 2:47am